SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS…
Leading Healthcare Institutions Adopt MSK-ACCESS for Liquid Biopsy Testing
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing…
Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor
NEW YORK and LONDON and MUNICH and NEW DELHI, Feb. 11, 2025…
Baylor Genetics Marks a Decade of Leadership in Precision Diagnostics, Empowering Patients, Healthcare Providers and Partners with Trusted Genetic Insights
HOUSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic…
Datar Cancer Genetics Unveils Next Generation Multi-Analyte, AI-Powered Decision Support Platform for Personalized Treatment of Difficult-to-Treat Cancers.
LONDON, MUNICH and NEW DELHI, Feb. 3, 2025 /PRNewswire/ -- Datar Cancer Genetics…
Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of In-Vitro Chemotherapy Effectiveness Tests for Cancer Patients
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar…
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving…
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
January 22, 2025 16:05 ET | Source: Adaptive Biotechnologies SEATTLE, Jan. 22,…
deCODE genetics: Complete recombination map of the human-genome, a major step in genetics
REYKJAVIK, Iceland, Jan. 22, 2025 /PRNewswire/ -- Scientists at deCODE genetics/Amgen have constructed…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…